Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
Profound Medical (NASDAQ:PROF) will release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026.
Rhea-AI Summary
Profound Medical (NASDAQ:PROF) will release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and business developments. A live webcast and archived recording will be available in the company Investors section.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PROF
In the Feb 13 session, PROF gained 5.94%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings release date
- March 5, 2026
- Q4 and full year 2025 results release after market close
- Conference call time
- 4:30 p.m. ET
- Management call to discuss Q4 and full year 2025 results
- Results period
- Full year 2025
- Financial results coverage period
- Quarter reported
- Fourth quarter 2025
- Quarterly results to be discussed on call
Historical Context
-
PRO FAMILIA hospital reached 500th Sonalleve procedure and highlighted global usage.
-
Company outlined participation in two upcoming investor events in February 2026.
-
Mount Sinai performed its first TULSA-PRO procedure, expanding U.S. adoption.
-
Year-end TULSA-PRO installed base reached 78 systems, exceeding 2025 goal.
-
Johns Hopkins treated its first commercial TULSA-PRO prostate cancer patient.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
imri medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Fourth Quarter and Full Year 2025 Results Conference Call Details:
Date: Thursday, March 5, 2026
Time: 4:30 p.m. ET
Live Call Registration: https://register-conf.media-server.com/register/BI9b6f3d29fd3749db83543442274147c2
The call will also be broadcast live and archived on the Company's website in the Investors section here.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.